Phase Ib/II Trial of High Dose Ascorbic Acid (AA) with Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have No Prior Therapy for Their Metastatic Pancreatic Cancer
Summary
The purpose of this phase Ib/II study is to see if a treatment regimen with a combination of paclitaxel protein bound (also known as nab-paclitaxel), gemcitabine, and cisplatin when given with high dose Ascorbic Acid will be safe and effective in individuals with untreated metastatic pancreatic cancer.
General Information
NCT#: NCT03410030
Study ID: SU2C HRI NPG-002
Trial Phase: Phase I/II
Trial Sponsor: SU2C - Stand Up to Cancer, Translational Genomics Research Institute (TGen), HonorHealth Research Institute, Lustgarten Foundation, Princeton University, University of Arizona
Therapies Used in This Trial: Nab-paclitaxel, Gemcitabine, Ascorbic Acid, Cisplatin